NCT05175768

Study to Evaluate the Effect of Nicotinamide Mononucleotide (NMN) As an Adjuvant to Standard of Care (SOC) On Fatigue Associated With COVID-19 Infection

A Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Effect of Nicotinamide Mononucleotide (NMN) As an Adjuvant to Standard of Care (SOC) On Fatigue Associated With COVID-19 Infection

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 69 (actual)
• Sponsor: Vedic Lifesciences Pvt. Ltd. · Industry
• Sex: All
• Age: 40 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

A Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Effect of Nicotinamide Mononucleotide (NMN) As an Adjuvant to Standard of Care (SOC) On Fatigue Associated with COVID-19 Infection

Conditions

• COVID-19 Infection

Interventions

Type	Name	Description
OTHER	Nicotinamide Mononucleotide	Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
OTHER	Nicotinamide Mononucleotide with L-Leucine	Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
OTHER	Placebo	Two sachets to be taken orally after breakfast and Two sachets after lunch with water.

Timeline

• Start date: 2021-12-27
• Primary completion: 2022-07-16
• Completion: 2022-07-16
• First posted: 2022-01-04
• Last updated: 2024-09-23

Locations

12 sites across 1 country: India